Blog - Page 2447 of 5623

MondayNov 14, 2016 2:04 am

GainClients, Inc. (GCLT) is “One to Watch”

GainClients, Inc. is a software service company focused primarily on the development of marketing services for real estate professionals and valuable home search and area information tools for consumers. The company's innovations expound the popularity of online networks by helping real estate professionals better serve their clients through the sharing of accurate real estate data. The company's main product is the GCard progressive networking system, which is designed to build and promote relationships among real estate professionals and their clients. Using the GCard, agents and brokers have the means to offer real estate, lending and title services information through an…

FridayNov 11, 2016 4:26 pm

Singlepoint, Inc. (SING) CEO Reflects on Impact of Election Day Results on MoneyTV with Donald Baillargeon

Before the opening bell, Singlepoint, Inc. (OTC: SING) was announced as a featured company on this week’s episode of MoneyTV with Donald Baillargeon. MoneyTV is an internationally syndicated television program about “money and what makes it happen.” The show includes informative interviews with company CEOs, offering prospective investors insight into their operations and outlooks for the future. To view this week’s program, visit www.MoneyTV.net In the interview, Greg Lambrecht, chief executive officer of Singlepoint, reflected on Tuesday’s polling results, particularly as they relate to the legalization of recreational and medicinal marijuana in states across the country. In total, four states…

FridayNov 11, 2016 1:53 pm

Achaogen, Inc. (AKAO) Attacks Super Bugs: Plazomicin Phase III Trials Are Underway

The era of the super bug is upon us, and Achaogen, Inc. (NASDAQ: AKAO) has joined the fray against them. For close to one hundred years, antibiotics have lowered the prevalence and severity of infectious diseases. Increasingly, though, it is becoming apparent that the bacterial world is fighting back. Infections of the urinary tract (UTI) and others such as acne, bronchitis and streptococcal pharyngitis (strep throat) are becoming more resistant to the antibiotics that are most commonly prescribed to treat them. And this threat is compounded by the rise of the super bug, strains of bacteria that have already evolved…

FridayNov 11, 2016 1:17 pm

Monaker Group (MKGI) – A Growing Presence in Alternative Lodging Rental Market

The alternative lodging rental market is maturing quickly, being one of the fastest growing verticals in the travel industry over the last few years. Already believed to be worth more than $100 billion worldwide, the sector continues to expand rapidly as more and more vacation rentals companies are joining the game alongside the now-famous HomeAway, Booking.com and Airbnb. Monaker Group, Inc. (OTCQB: MKGI), a technology-driven travel group that offers comprehensive tourism solutions and personalized tours, already maintains an important presence in the alternative lodging market, with a portfolio of more than one million rental units available. The vacation rental market…

FridayNov 11, 2016 12:53 pm

Trevena, Inc. (TRVN) is “One to Watch”

Trevena, Inc. (NASDAQ: TRVN) is a clinical stage biopharmaceutical company focused on developing and delivering biased ligands to discover the next generation of GPCR targeted medicine. The company is focused on three product candidates: Oliceridine, for moderate to severe acute pain; TRV734, an oral use medicine for people in moderate, severe acute, and chronic pain; and TRV250, for those suffering from migraines. On November 7, 2016, Aegis Capital Corp. (http://dtn.fm/bB9sC) initiated coverage on Trevena, Inc., offering the company a 'Buy' rating with a target price of $14. This rating was released soon after the company reported its third quarter 2016…

FridayNov 11, 2016 10:28 am

Celldex Therapeutics, Inc. (CLDX) is “One to Watch”

Last month, Celldex Therapeutics, Inc. (NASDAQ: CLDX), a company in the business of developing targeted therapeutics for those suffering from devastating diseases for which current treatments are inadequate, found positive results from its phase II study of glembatumumab vedotin in patients with stage III/IV checkpoint inhibitor-refractory. The study showed that patients experienced a confirmed response, with 52% of patients experiencing tumor shrinkage. In addition, by close of market on November 8, 2016, Celldex stock was up significantly as investors reacted to the company’s third quarter earnings report, which surpassed estimates for revenue and EPS. CLDX’s stock rose by nearly 15%…

ThursdayNov 10, 2016 3:25 pm

Neuralstem, Inc. (CUR) May Lift the Blues with its Novel Neurogenetic NSI-189

Major Depressive Disorder (MDD) afflicts about 15 million Americans and is the leading cause of disability in the U.S. for those aged 15-44, according to the National Institute of Mental Health. Although experiencing the blues is part of the human condition, MDD is more than just the sadness that accompanies misfortune. MDD is a chronic feeling of enervation, loss of interest in activities, pessimism and hopelessness. At one time regarded as caused by supernatural forces, today, modern medical science generally attributes depression to chemical imbalances in the brain. However, with its small-molecule benzylpiperazine-aminopyridine drug NSI-189, Neuralstem, Inc. (NASDAQ: CUR) has…

ThursdayNov 10, 2016 11:40 am

Medical Transcription Billing, Corp. (MTBC) Announces Third Quarter Results

Before the opening bell, Medical Transcription Billing, Corp. (NASDAQ: MTBC; MTBCP) announced its financial and operational results for the third quarter of 2016, including a review of the October acquisition of MediGain, LLC and subsidiary Millennium Practice Management, LLC, which was the company’s largest acquisition to date. Notably, MTBC’s revenues for the three-month period were $5.3 million, up from $5.2 million in the previous quarter. The company also achieved its fourth consecutive quarter of positive adjusted EBITDA, reporting $130,000 for the third quarter and $209,000 year-to-date. “We are pleased to announce another quarter of quarter-over-quarter revenue growth,” Mahmud Haq, chairman…

ThursdayNov 10, 2016 10:17 am

Singlepoint, Inc. (SING) Set to Capitalize on Marijuana Industry Election Results

It is no secret that the United States is going through some serious changes when it comes to marijuana. In the recent election, several states approved the legalization of marijuana for recreational purposes, with other states voting to approve medical marijuana initiatives. With Donald Trump winning the presidential election, it brings forward the question: how will this new presidency affect the marijuana industry in the U.S.? Prior to the election, Alicia Wallace from the Cannabist (http://dtn.fm/8zKZ3) was able to share the four leading presidential candidates’ views on marijuana, including Trump’s. While the leading third-party candidates supported the legalization of marijuana,…

WednesdayNov 09, 2016 3:20 pm

Alder Biopharmaceuticals, Inc. (ALDR) Promises to Relieve Migraine Misery with Leading Drug Candidate ALD403

A research report (http://dtn.fm/w6uT3) issued earlier this week by Aegis Capital Corp. shows that Alder Biopharmaceuticals, Inc. (NASDAQ: ALDR) has lived up to its promise since 2004, when it received startup funding from the Army under the Small Business Technology Transfer (STTR) program. Since then the company has been working on the development of new production technologies for humanized antibodies. Now it is close to making the fruits of that research available for the treatment of migraine, inflammatory diseases and autoimmune diseases with its lead product candidate, ALD403. Results of ongoing clinical trials are quite promising. Trials of ALD403 go…

Site Search

Company Search